Real-world analysis of survival outcomes in advanced EGFR-mutant NSCLC patients treated with platinum-pemetrexed after EGFR-TKI treatment failure
Postoperative recurrence, first-line EGFR-TKI PFS ≥12 months and osimertinib treatment after platinum-pemetrexed predicted better OS, while BMI <18.5 predicted worse OS. Osimertinib treatment before platinum-pemetrexed treatment did not affect the efficacy of platinum-pemetrexed.
Authors
- Wei‐Yu Liao (ORCID: https://orcid.org/0000-0001-6383-3470)
- Chong‐Jen Yu (ORCID: https://orcid.org/0000-0001-5664-9392)
- Jin‐Yuan Shih (ORCID: https://orcid.org/0000-0002-2854-5067)
- James Chih‐Hsin Yang (ORCID: https://orcid.org/0000-0002-5586-5138)
- Zong-Han Yao
- Chao‐Chi Ho
- Kuan‐Yu Chen
- Chin-Yao Yang
Institutions
- National Taiwan University Hospital (TW)
Publication Details
- Journal
- Journal of the Formosan Medical Association
- Published
- 2024-08-15
- DOI
- https://doi.org/10.1016/j.jfma.2024.08.017
- Citations
- 7
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 2.93